Dr. Sherwat, Dr. Petersen and Dr. Wilkin join Dr. Fryhofer for a discussion about tecovirimat, or “TPOXX”, for the treatment of monkeypox in infected individuals. The discussion provides background on TPOXX, including its current status, availability and access while the drug is under an investigational new drug application. An overview of the recently announced National Institute of Allergy and Infectious Diseases sponsored Phase 3 clinical trial evaluating TPOXX is also provided. A moderated question and answer session is held at the end of the discussion to help address any confusion or misinformation about patient access to TPOXX.

свернуть